- Home
- FMST vs TOVX Comparison
FMST vs TOVX Comparison
Compare FMST & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FMST | TOVX |
|---|---|---|
| Founded | 2005 | 2001 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 11.1M |
| IPO Year | 2022 | 2012 |
Fundamental Metrics
Financial Performance| Metric | FMST | TOVX |
|---|---|---|
| Price | $0.72 | $0.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 269.3K | ★ 1.0M |
| Earning Date | 11-24-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.42 | $0.14 |
| 52 Week High | $3.49 | $0.49 |
Technical Indicators
Market Signals| Indicator | FMST | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 54.43 | 34.67 |
| Support Level | $0.45 | N/A |
| Resistance Level | $0.90 | $0.25 |
| Average True Range (ATR) | 0.09 | 0.02 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 58.75 | 39.48 |
Price Performance
Historical ComparisonAbout FMST Foremost Lithium Resource & Technology Ltd.
Foremost Clean Energy Ltd is an exploration company focused on the identification and development of high potential mineral opportunities in stable jurisdictions. Its Uranium properties includes Eastern Athabasca, and Blue-Sky. Its Lithium properties includes Zoro Lithium Project, JEAN LAKE LITHIUM GOLD PROJECT, Peg North Project, Grass River Claims Project, and JOL LITHIUM PROJECT.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.